文獻回顧乳癌婦女接受紫杉醇治療引發周邊神經病變之現況及其評估工具

Taxane-induced Peripheral Neuropathy and Its Assessment Tool in Women with Breast Cancer: A Literature Review

10.3966/168395442016061601002

鄭有妏(You-Wun Jheng)；王雅容(Ya-Jung Wang)

化學治療 ； 乳癌婦女 ； 周邊神經病變 ； 紫杉醇 ； chemotherapy ； female breast cancer ； peripheral neuropathy ； taxanes

腫瘤護理雜誌

16卷1期（2016 / 06 / 01）

7 - 14

繁體中文

紫杉醇引發周邊神經病變（taxane-induced peripheral neuropathy, TIPN）是乳癌婦女接受紫杉醇治療後最常見且嚴重的副作用之一，其被形容為對稱性「末梢枯死」現象，這意味著症狀最先影響其雙腳趾或手指，輕者有末端肢體感覺異常，重者則出現運動或自主神經症狀，甚至干擾個案日常活動及降低生活品質，故護理人員應正視此問題。本文旨在以文獻回顧方式，論述紫杉醇引發周邊神經病變之病生理機轉、臨床表徵、相關因素與主客觀評估工具，期望可協助護理人員了解此概念，作為臨床照護的參考依據。

Taxane-induced peripheral neuropathy (TIPN) is one of the common but serious adverse events occurring in breast cancer patients receiving taxane chemotherapy. TIPN is generally described as a symmetrical “dying-back” phenomenon, meaning it affects the toes or fingertips first. The mild symptom is paresthesia of the extremities and the severe neuropathy occurs in the motor or autonomic systems to sometimes even interfere with the daily activities and reduce patient's quality of life. Therefore, nurses should pay more attention to this issue. This article aims to review the pathophysiologic mechanisms, clinical manifestations, TIPN related factors, and assessment tools including both subjective and objective ones. The purposes of this literature review are to help nurses identify TIPN and to provide reference for clinical care.

1. Argyriou, A. A.,Koltzenburg, M.,Polychronopoulos, P.,Papapetropoulos, S.,Kalofonos, H. P.(2008).Peripheral nerve damage associated with administration of taxanes in patients with cancer.Critical Reviews in Oncology/Hematology,66(3),218-228.
2. Armstrong, T.,Almadrones, L.,Gilbert, M. R.(2005).Chemotherapy-induced peripheral neuropathy.Oncology Nursing Forum,32(2),305-311.
3. Bhatnagar, B.,Gilmore, S.,Goloubeva, O.,Pelser, C.,Medeiros, M.,Chumsri, S.,Bao, T.(2014).Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: A single-center experience.Springerplus,3(366),1-6.
4. Blum, J. L.,O’Shaughnessy, J. A.(2006).Capecitabine/Taxane combination therapy: Evolving clinical utility in breast cancer.Clinical Breast Cancer,7(1),42-50.
5. Brem, S.,Kumar, N. B.(2011).Management of treatment-related symptoms in patients with breast cancer.Clinical Journal of Oncology Nursing,15(1),63-71.
6. Carlson, K.,Ocean, A. J.(2011).Peripheral neuropathy with microtubule-targeting agents: Occurrence and management approach.Clinical Breast Cancer,11(2),73-81.
7. Cavaletti, G.,Frigeni, B.,Lanzani, F.,Mattavelli, L.,Susani, E.,Alberti, P.,Bidoli, P.(2010).Chemotherapy-induced peripheral neurotoxicity assessment: A critical revision of the currently available tools.European Journal of Cancer,46(3),479-494.
8. Cavaletti, G.,Jann, S.,Pace, A.,Plasmati, R.,Siciliano, G.,Briani, C.,Giussani, G.(2006).Multi-center assessment of the total neuropathy score for chemotherapy-induced peripheral neurotoxicity.Journal of the Peripheral Nervous System,11(2),135-141.
9. Cella, D.,Peterman, A.,Hudgens, S.,Webster, K.,Socinski, M. A.(2003).Measuring the side effects of taxane therapy in oncology: The functional assesment of cancer therapy-taxane (FACT-Taxane).Cancer,98(4),822-831.
10. Eckhoff, L.,Knoop, A. S.,Jensen, M. B.,Ewertz, M.(2015).Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors.European Journal of Cancer,51(3),292-300.
11. Hausheer, F. H.,Schilsky, R. L.,Bain, S.,Berghorn, E. J.,Lieberman, F.(2006).Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy.Seminars in Oncology,33(1),15-49.
12. Lee, J. J.,Swain, S. M.(2006).Peripheral neuropathy induced by microtubule-stabilizing agents.Journal of Clinical Oncology,24(10),1633-1642.
13. Loprinzi, C. L.,Reeves, B. N.,Dakhil, S. R.,Sloan, J. A.,Wolf, S. L.,Burger, K. N.,Lachance, D. H.(2011).Natural history of paclitaxel-associated acute pain syndrome: Prospective cohort study NCCTG N08C1.Journal of Clinical Oncology,29(11),1472-1478.
14. Moulder, S. L.,Holmes, F. A.,Tolcher, A. W.,Thall, P.,Broglio, K.,Valero, V.,Hortobagyi, G. N.(2010).A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer.Cancer,116(4),814-821.
15. Park, S. B.,Goldstein, D.,Krishnan, A. V.,Lin, C. S.,Friedlander, M. L.,Cassidy, J.,Kiernan, M. C.(2013).Chemotherapy-induced peripheral neurotoxicity: A critical analysis.A Cancer Journal for Clinicians,63(6),419-437.
16. Peto, R.,Davies, C.,Godwin, J.,Gray, R.,Pan, H. C.,Clarke, M.,Pritchard, K.(2012).Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.Lancet,379(9814),432-444.
17. Schneider, B. P.,Zhao, F.,Wang, M.,Stearns, V.,Martino, S.,Jones, V.,Sparano, J. A.(2012).Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer.Journal of Clinical Oncology,30(25),3051-3057.
18. Shimozuma, K.,Ohashi, Y.,Takeuchi, A.,Aranishi, T.,Morita, S.,Kuroi, K.,Hausheer, F. H.(2009).Feasibility and validity of the patient neurotoxicity questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02.Support Care Cancer,17(12),1483-1491.
19. Smith, E. M.(2013).Current methods for the assessment and management of taxane-related neuropathy.Clinical Journal of Oncology Nursing,17,22-34.
20. Stubblefield, M. D.,Burstein, H. J.,Burton, A. W.,Custodio, C. M.,Deng, G. E.,Ho, M.,Tummala, S.(2009).NCCN task force report: Management of neuropathy in cancer.Journal of the National Comprehensive Cancer Network,7(Suppl 5),1-26.
21. Tanabe, Y.,Hashimoto, K.,Shimizu, C.,Hirakawa, A.,Harano, K.,Yunokawa, M.,Fujiwara, Y.(2013).Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer.International Journal of Clinical Oncology,18(1),132-138.
22. Tofthagen, C.(2010).Patient perceptions associated with chemotherapy-induced peripheral neuropathy.Clinical Journal of Oncology Nursing,14(3),E22-E28.
23. Tofthagen, C.,Overcash, J.,Kip, K.(2012).Falls in persons with chemotherapy-induced peripheral neuropathy.Supportive Care in Cancer,20(3),583-589.
24. 衛生福利部國民健康署（2015，4月29日）．民國101年癌症登記報告．2015年8月20日取自http://www.hpa.gov.tw/BHPNet/Web/Stat/StatisticsShow.aspx?No=201504290001 [Ministry of Health and Welfare Health Promotion Administration, Taiwan, ROC (2015, April 29). Cancer registry annual report, 2012: Taiwan. Retrieved August 20, 2015 from http://www.hpa.gov.tw/BHPNet/Web/Stat/StatisticsShow.aspx?No=201504290001]

1. 蕭雅群,鄭惠蘭,劉佩婷,孫婉綾,李淑慧(2023)。降低神經毒性化療藥物引起周邊神經病變改善專案。腫瘤護理雜誌，23(1)，53-68。
2. 楊婷婷,紀慧真(2021)。一位乳癌手術患者首次接受化學治療引起周邊神經病變之護理經驗。腫瘤護理雜誌，21(增訂刊II)，57-68。